FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.
First Preloaded Toric Available in the United States and Monofocal Option Combine Consistent IOL Delivery with Outstanding Visual Outcomes of enVista® LAVAL, QC, Oct. 27, 2020 /PRNewswire/ -- Bausch + ...
Celebrating 75 years of intraocular lens advancements that have improved care for millions of cataract patients. On November 29, 1949, Sir Harold Ridley performed a surgical procedure to replace a ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...